Visible fat loss and body composition changes typically appear around weeks 4 to 6, with full benefits developing over 8 to 12 weeks

usually improves over several weeks Diarrhoea or constipation : Altered bowel habits due to delayed gastric emptying Abdominal discomfort : Bloating, dyspepsia, or gastro-oesophageal reflux symptoms Practical management strategies recommended by NICE and specialist diabetes services include: Starting at the lowest licensed dose and titrating gradually according to the product's summary of product characteristics Eating smaller, more frequent meals and avoiding high-fat foods Maintaining adequate hydration, particularly if experiencing vomiting or diarrhoea Taking the injection at a consistent time as specified in the SmPC for your particular medication Less common but important adverse effects include: Injection site reactions : Rotate injection sites systematically between abdomen, thigh, and upper arm to minimise localised reactions Hypoglycaemia : Risk increases when GLP-1 agents are combined with insulin or sulphonylureas

In a Phase I single-blind, placebo-controlled trial, 3 male volunteers received subcutaneous MT-2 injections (0.01-0.03 mg/kg) on alternating days for 2 weeks
It also affects your brain and central nervous system pathways that regulate digestion, potentially contributing to altered bowel function beyond the direct GI tract effects
It plays a key role in energy production because it transports fatty acids 2 into your cells mitochondria
Rotate between recommended injection sitesabdomen, thigh, and upper armand avoid injecting into the same spot repeatedly